Default

Allergy and immunology

Anaesthesia

Basic research

Cardiovascular medicine

Complementary medicine and alternative therapies

Critical care / intensive care

Dentistry / oral medicine

Dermatology

Emergency medicine

Endocrinology

Epidemiology

Ethics

Evidence-based medicine

Gastroenterology

Genetics

Geriatric medicine / aging

Haematology / blood transfusion

Health economics

Health policy

History of medicine

Infectious diseases

Internal medicine

Laboratory medicine

Medical education

Medical informatics

Neurology

Nursing

Nutrition and metabolism

Obstetrics and gynaecology

Occupational and environmental medicine

Oncology

Ophthalmology

Organisation of health care

Otolaryngology / head and neck surgery

Paediatrics

Palliative care

Pathology

Patient-physician relationship

Pharmacology and therapeutics

Primary care, family medicine

Psychiatry and psychotherapy

Psychosomatics

Public health

Quality of care

Radiology

Rehabilitation medicine

Renal medicine

Respiratory medicine

Rheumatology

Sexual medicine

Sports medicine

Statistics and research methods

Surgery

Transplantation

Travel medicine

Urology

Ops! No article found. Reset filter

Multimodal treatment strategies for colorectal liver metastases

Review article: Biomedical intelligence
Birrer DL, Tschuor C, Reiner C, Fritsch R, Pfammatter T, Garcia Schüler H, Pavic M, De Oliveira M, Petrowsky H, Dutkowski P, Oberkofler C, Clavien PA
Swiss Med Wkly. 2021;151:w20390

The optimal treatment of patients with colorectal liver metastases requires the timely association of various strategies, and all cases must be discussed at multidisciplinary team conferences. While colorectal liver metastases was a uniformly lethal condition a few decades ago, it has become amenable to curative therapies, with excellent quality of life in many scenarios. This review reports on up-to-date treatment modalities and their combinations in the treatment algorithm of colorectal liver metastases.

Gestational trophoblastic disease in Switzerland: retrospective study of the impact of a regional reference centre

Original article
Fehlmann A, Benkortbi K, Rosseel G, Meyer-Hamme U, Tille JC, Sloan-Bena F, Paoloni-Giacobino A, Rougemont AL, Bodmer A, Botsikas D, Mathevet P, Petignat P, Undurraga Malinverno M
Swiss Med Wkly. 2021;151:w20406

The European Society of Medical Oncology recommends that countries should have reference centres to provide adequate diagnosis and treatment of gestational trophoblastic disease. This study reflects the activity of the Swiss trophoblastic disease centre from the French-speaking part of Switzerland created in 2009, and its role as local and national reference centre, in terms of global health, for women with gestational trophoblastic disease.

Autophagy and coronavirus infection – a Trojan horse or Achilles heel?

Viewpoint
Seiler K, Tschan MPP
Swiss Med Wkly. 2021;151:w20468

Many of the more promising compounds currently investigated in clinical trials are autophagy modulators, thus substantiating the need for an understanding of how coronaviruses interact with and utilise components of the autophagy pathway.

Haemophagocytic lymphohistiocytosis and liver failure-induced massive hyperferritinaemia in a male COVID-19 patient

Original article
Zellweger NM, Huber J, Tsakiris DA, Tzankov A, Gebhard CE, Siegemund M
Swiss Med Wkly. 2021;151:w20420

The authors present the case of a 58-year-old man with the unique combination of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and, later on, haemophagocytic lymphohistiocytosis admitted to the intensive care unit.

Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis

Review article: Medical guidelines
Schwotzer R, Flammer AJ, Gerull S, Pabst T, Arosio P, Averaimo M, Bacher VU, Bode P, Cavalli A, Concoluci A, Dirnhofer S, Djerbi N, Dobner SW, Fehr T, Garofalo M, Gaspert A, Heimgartner R, Hübers A, Jung HH, Kessler C, Knöpfel R, Laptseva N, Manka R, Mazzucchelli L, Meyer M, Mihaylova V, Monney P, Mylonas A, Nkoulou R, Pazhenkottil A, Pfister O, Rüfer A, Schmidt A, Seeger H, Stämpfli SF, Stirnimann G, Suter T, Théaudin M, Treglia G, Tzankov A, Vetter F, Zweier M, Gerber B
Swiss Med Wkly. 2020;150:w20364

These are the Swiss Amyloidosis Network recommendations which focus on diagnostic work-up and treatment of AL-amyloidosis. One aim of this meeting was to establish a consensus guideline regarding the diagnostic work-up and the treatment recommendations for systemic amyloidosis tailored to the Swiss health care system.

Multisystem inflammatory syndrome with refractory cardiogenic shock due to acute myocarditis and mononeuritis multiplex after SARS-CoV-2 infection in an adult

Original article
Othenin-Girard A, Regamey J, Lamoth F, Horisberger A, Glampedakis E, Epiney JB, Kuntzer T, de Leval L, Carballares M, Hurni CA, Rusca M, Pantet O, Di Bernardo S, Oddo M, Comte D, Piquilloud L
Swiss Med Wkly. 2020;150:w20387

Multisystem inflammatory syndrome associated with SARS-CoV-2 can occur in adults. The clinical presentation can include severe organ damage with features of incomplete or complete Kawasaki disease, including coronary aneurysm, as well as myocarditis-associated cardiogenic shock and also mononeuritis multiplex.

Concordance of tumour characteristics and survival clustering among pairs of first-degree relatives with breast cancer

Original article
Rapiti E, Tille JC, Fournier E, Saiji E, Weintraub D, Bouzourene H, Viassolo V, Bouchardy C, Chappuis PO, Benhamou S
Swiss Med Wkly. 2020;150:w20327

Family history is a known risk factor for breast cancer, but its prognostic value and the prognostic value of tumour characteristics in relation to family history has not been clearly established.

Clinical course of COVID-19 pneumonia in a patient undergoing pneumonectomy and pathology findings during the incubation period

Original article
Çınar HU, İnce Ö, Çelik B, Saltabaş F, Özbek M
Swiss Med Wkly. 2020;150:w20302

The case presented here represents an “incidental” sampling of a lung infected with SARS-CoV-2, as a result of surgery for lung cancer at a time when the lung infection did not produce symptoms. This gave the opportunity to examine the pathology of COVID-19 pneumonia during the incubation period.

Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?

Viewpoint
Negro F
Swiss Med Wkly. 2020;150:w20249

The pathogenesis of COVID-19 is currently believed to proceed via both directly cytotoxic and immune-mediated mechanisms. An additional mechanism facilitating viral cell entry and subsequent damage may involve the so-called antibody-dependent enhancement (ADE).

Non-invasive diagnosis of liver steatosis: ready for primetime?

Viewpoint
Goossens N
Swiss Med Wkly. 2019;149:w20108

The formal diagnosis of hepatic steatosis relies on liver histology based on a liver biopsy, which is an invasive procedure that is not required in the majority of cases. Due to the high prevalence of liver steatosis, in particular in the context of an increase in NAFLD incidence, there has been renewed interest in use of non-invasive tools to assess the presence of liver disease.

Verpassen Sie keinen Artikel!

close